2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Lactate Dehydrogenase
  5. Lactate Dehydrogenase Inhibitor

Lactate Dehydrogenase Inhibitor

Lactate Dehydrogenase Inhibitors (81):

Cat. No. Product Name Effect Purity
  • HY-W013032A
    Oxamic acid sodium
    		Inhibitor 99.72%
    Oxamic acid (oxamate) sodium salt is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid sodium salt shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis.
  • HY-100681
    GSK2837808A
    		Inhibitor 99.24%
    GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
  • HY-16214
    FX-11
    		Inhibitor 99.21%
    FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts.
  • HY-100742A
    (R)-GNE-140
    		Inhibitor 99.77%
    (R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC50s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.
  • HY-182469
    FuBIG
    		Inhibitor
    FuBIG is an iminoguanidine derivative with neuroprotective effects. FuBIGL inhibits L-LDH activation and reduces lactate production. FuBIGL exerts protective effects on inflammatory nerve cells, upregulates the expressions of AMPK, pAMPK and FOXO3, and activates the AMPK pathway in cells. FuBIG exerts anti-inflammatory effects by reducing pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and increasing the anti-inflammatory cytokine IL-10. FuBIG maintains mitochondrial membrane potential, alleviates mitochondrial dysfunction, reduces ROS production, and relieves oxidative stress. FuBIG upregulates Bcl-2, downregulates Bax and Caspase-3, and inhibits cell apoptosis (apoptosis). FuBIG improves metabolic disorders in diabetic mice, decreases the levels of LDL-C, ALT and AST, and increases HDL-C level simultaneously. FuBIG can be used in the research of diabetic neuroinflammation.
  • HY-116509
    Linoleylanilide
    		Inhibitor
    Linoleylanilide (Linoleic acid anilide) is a Linoleic acid (HY-N0729) derivative. Linoleylanilide slightly inhibits the PMA (HY-18739)-induced expression of CD11b. Linoleylanilide inhibits serum LDH, GOT and GPT activities. Linoleylanilide decreases red cell counts and hemoglobin content.
  • HY-W040118
    Galloflavin
    		Inhibitor 99.36%
    Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated Kis for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production.
  • HY-W013032
    Oxamic acid
    		Inhibitor 99.98%
    Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis.
  • HY-147216
    AXKO-0046
    		Inhibitor 99.77%
    AXKO-0046, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor.AXKO-0046 has LDHB inhibitory activity with an EC50 value of 42 nM.AXKO-0046 can be used for the research of cancer metabolism.
  • HY-113486
    Lathosterol
    		Inhibitor 98.09%
    Lathosterol is a plant sterol and cholesterol-like molecule. Lathosterol increases antioxidant enzymes (such as SOD, CAT, and GSH) and decreases LDH. Lathosterol has a hepatoprotective effect on mice with acetaminophen (HY-66005)-induced liver injury[1].
  • HY-101374A
    AGN 192403 hydrochloride
    		Inhibitor 99.96%
    AGN 192403 (BRD4780) hydrochloride is a potent and selective imidazoline-1 receptor antagonist with a Ki value of 42 nM. AGN 192403 hydrochloride is also a TMED9 inhibitor. AGN 192403 hydrochloride shows protective effects on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. AGN 192403 hydrochloride mitigates the proliferation and migration of differentiated glioma tumor cells. AGN 192403 hydrochloride can be used for glioma tumor and neurological diseases research.
  • HY-100742
    GNE-140 racemate
    		Inhibitor 99.25%
    GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor.
  • HY-N6948
    Linalyl acetate
    		Inhibitor 98.80%
    Linalyl acetate is the principal components of many plant essential oils. Linalyl acetate exhibits anti-anxiety, anti-inflammatory, anti-diabetic, anti-stress, and cardiovascular-regulatory effects. Linalyl acetate is orally active.
  • HY-139319
    LDHA-IN-3
    		Inhibitor 99.88%
    LDHA-IN-3 (compound 2), as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). LDHA-IN-3 can be used for the research of cancer.
  • HY-121983
    CAY10594
    		Inhibitor 98.64%
    CAY10594 is an orally active PLD2 inhibitor with an IC50 of 140 nM. CAY10594 has activities such as anti-tumor, anti-oxidation and liver protection. CAY10594 can be used for the research of diseases like breast cancer, acute liver injury and colitis.
  • HY-132606A
    Nedosiran sodium
    		Inhibitor
    Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate.
  • HY-111108
    LDH-IN-1
    		Inhibitor 99.84%
    LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
  • HY-18968
    AZ-33
    		Inhibitor 98.06%
    AZ-33 (LDHA-IN-4) (compound 33) is a selective lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 0.5 μM and a Kd of 0.093 μM.
  • HY-113098
    2-Oxovaleric acid
    		Inhibitor
    2-Oxovaleric acid is an analog of Pyruvate and a substrate inhibitor of Lactate dehydrogenase, exhibiting substrate inhibitory activity against lactate dehydrogenase from Phycomyces blakesleeanus.
  • HY-147216A
    AXKO-0046 dihydrochloride
    		Inhibitor 99.71%
    AXKO-0046 dihydrochloride, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor. AXKO-0046 dihydrochloride has LDHB inhibitory activity with an EC50 value of 42 nM. AXKO-0046 dihydrochloride can be used for the research of cancer metabolism.